Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy infants and adolescents aged 6 month to 19 years~2. study Subject was born at full term pregnancy(37 weeks)~3. study Subject who understand the details of this clinical trial, decide voluntarily to participate the trial, and signed the Informed Consent Form (less than 7 years of age, written informed consent by study subject's legal guardians)~Exclusion Criteria:~1. Those with a history of allergic reaction to eggs or chicken, the vaccine components~2. Those who had been ad ministered the influenza vaccine 6 months prior to the study drug vaccination~3. Those with immunologic impairment including immune deficiency disorders or family history about it.~4. Those with a history of Guillain-Barre syndrome~5. Those with a history of Down's syndrome or cytogenetic disorders~6. Those who would be ineligible to participate the study as follows: serious chronic disease (cardiovascular system disease; excluding controlled hypertension and respiratory system disease; including respiratory failure, metabolic disease, renal dysfunction, hemoglobinopathy, etc)~7. Hemophilia patients at risk of serious bleeding with intramuscular injection or those receiving anticoagulant therapy~8. Those who have active infection or who have fever higher than 38.0℃ within 72 hours prior to the dosing of study drug~9. Those who had been vaccinated with another vaccine within 28 days prior to the dosing of study drug or had a scheduled vaccination during the clinical trial period~10. Those who had received an immunosuppressant, immunity-modifying drug within 3 months prior to the dosing of study drug - (1) Azathioprine, Cyclosporin, Interferon, G-CSF, Tacrolimus, Everolimus, Sirolimus, etc., (2) Those receiving high dose of corticosteroid(15mg/day of prednisolone is acceptable, but study subject used consistently 2mg/kg more than 14days is considered a high dose, so excluded in this clinical trial. However, inhalated, intra nasal and topical administration is acceptable regardless of dose.~11. Those who had received immunoglobulin or a blood-derived product within 3 months prior to the dosing of study drug or is scheduled to receive those products during the study period~12. Those who had taken antipyretic/analgesic/nonsteroidal antiinflammatory drugs within 4 hours prior to the dosing of study drug~13. study Subject who had participated in other clinical trial within 28 days prior to the study vaccination~14. Those whose clinically significant medical or psychiatric condition at the discretion of the investigator that would be ineligible to participate the study

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 19 Years
- Healthy Volunteers: t

Study Arms:
- GC3110A (Type: EXPERIMENTAL): One injection : 0.5ml or 0.25ml, IM on day 0 Two injection : 0.5ml or 0.25ml, IM on day 0
- GCFLU Pre-filled Syringe inj. (Type: ACTIVE_COMPARATOR): One injection : 0.5ml or 0.25ml, IM on day 0 Two injection : 0.5ml or 0.25ml, IM on day 0

Based on this trial design, predict the completion outcome and termination type (if applicable).